文献速递头痛与眩晕

fremanezumab长期治疗偏头痛的安全性与疗效随机研究

Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study.
PubMed 文献 · Neurology · 2020-09-10

该52周多中心随机双盲平行组研究评估fremanezumab按月或按季治疗成人慢性偏头痛(CM)或发作性偏头痛(EM)的长期安全性、耐受性和疗效。共入组1890例患者,最常见不良事件为注射部位反应(硬结33%、疼痛31%、红斑26%)。fremanezumab持续减少每月偏头痛天数、中重度头痛天数及急性头痛药物使用天数,并改善头痛相关残疾,长达12个月。

要点

  • fremanezumab按月或按季给药在CM和EM患者中耐受性良好。
  • 治疗12个月持续减少每月偏头痛天数和中重度头痛天数。
  • 注射部位反应是最常见不良事件,硬结33%、疼痛31%、红斑26%。

核心结论

  • fremanezumab按季或按月给药耐受性良好,并在长达12个月内持续改善偏头痛天数、头痛天数及头痛相关残疾。

研究设计与样本

  • 52周、多中心、随机、双盲、平行组研究,评估fremanezumab按月或按季治疗成人慢性偏头痛(CM)或发作性偏头痛(EM)。
  • 共入组1890例患者,其中CM按季551例、按月559例,EM按季394例、按月386例。

主要发现

  • 最常见不良事件为注射部位反应:硬结33%、疼痛31%、红斑26%。
  • 从基线至12个月,每月偏头痛天数减少:CM按季-7.2天、CM按月-8.0天、EM按季-5.2天、EM按月-5.1天。
  • 从基线至12个月,中重度头痛天数减少:CM按季-6.4天、CM按月-6.8天、EM按季-4.4天、EM按月-4.2天。
  • 任何急性头痛药物使用天数和头痛相关残疾的减少在12个月内维持。

临床怎么用

  • 对于CM或EM成人患者,可考虑fremanezumab按月或按季给药以预防偏头痛,并关注注射部位反应。

局限性

  • 证据等级为Class IV,提示长期fremanezumab治疗安全、耐受良好且持续有效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the long-term safety, tolerability, and efficacy of fremanezumab, a fully humanized monoclonal antibody approved for the preventive treatment of migraine. METHODS: A 52-week, multicenter, randomized, double-blind, parallel-group study evaluated fremanezumab monthly or quarterly in adults with chronic migraine (CM) or episodic migraine (EM). Safety and tolerability were assessed by adverse event (AE) monitoring (performed by the investigators), systematic local injection-site assessments (immediately and 1 hour after injection), laboratory/vitals assessments, and immunogenicity testing. Prespecified exploratory evaluations included change from baseline in the monthly number of migraine days, headache days of at least moderate severity, and days with any acute headache medication use. Change from baseline in headache-related disability (6-item Headache Impact Test scores) was also measured. RESULTS: Of 1,890 patients enrolled, 551 and 559 patients with CM received quarterly and monthly dosing; 394 and 386 patients with EM received quarterly or monthly, respectively. The most commonly reported AEs were injection-site reactions (induration 33%, pain 31%, and erythema 26%). Fremanezumab reduced monthly migraine days (CM quarterly -7.2 days, CM monthly -8.0 days, EM quarterly -5.2 days, EM monthly -5.1 days) and headache days of at least moderate severity (CM quarterly -6.4 days, CM monthly -6.8 days, EM quarterly -4.4, EM monthly -4.2 days) from baseline to 12 months. Reductions in any acute headache medication use and headache-related disability were also maintained over 12 months. CONCLUSIONS: Fremanezumab quarterly and fremanezumab monthly were well tolerated and demonstrated sustained improvements in monthly migraine days, headache days, and headache-related disability for up to 12 months in patients with migraine. CLINICALTRIALSGOV: NCT02638103. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that long-term fremanezumab treatment is safe, well tolerated, and effective at sustaining reductions in monthly migraine and headache days.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Goadsby PJ, Silberstein SD, Yeung PP, et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study. Neurology. 2020. PMID: 32913018. doi:10.1212/WNL.0000000000010600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。